Breast Cancer Women on Aromatase Inhibitors Treatment (B-ABLE)
Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized
About this trial
This is an interventional prevention trial for Osteoporosis focused on measuring osteoporosis, aromatase inhibitors, breast cancer, microindentation, arthralgia, musculoskeletal pain
Eligibility Criteria
Inclusion Criteria:
- Postmenopausal women with early breast cancer estrogen receptor with aromatase inhibitors treatment
Exclusion Criteria:
- Previous treatment with antiresorptive treatment for osteoporosis secondary osteoporosis, as corticosteroids, Hyperparathyroidism, Kidney Chronic disease, previous treatment with aromatase inhibitors Diabetes mellitus type 1 Fibromyalgia
Sites / Locations
- Xavier NoguesRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
AI with osteoporosis
AI without osteoporosis
Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.